Etcamah

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Breast CancerOvarian CancerER+ HER2- Advanced Breast CancerEstrogenEarly Breast Cancer

706 competitors in Breast Cancer

#DrugCompanyPhaseTrials

1

Etcamah

AstraZeneca

Phase 3

12

Lexiscan

Astellas

Preclinical

13

Zolymbus

AbbVie

Preclinical

14

Blenoxane

Bristol-Myers Squibb

Preclinical

15

Methylthioninium Chloride

PProvepharm SAS

Preclinical

36

Spravato

WWim Janssens

Preclinical

27

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

18

Acupan

YYonsei University

Preclinical

19

Chantix

PPrism Pharmaceuticals

Preclinical

110

Nubain

AAultman Health Foundation

Preclinical

1Show 26 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Advanced Breast Cancer2 trials

A Randomised, Open-Label, Phase III Study of Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With Physician's Choice CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant for the First-Line Treatment of Patients With BRCA1, BRCA2, or PALB2 Mutations and Hormone Receptor Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified) Advanced Breast Cancer (EvoPAR-Breast01)

Recruiting·AstraZeneca·Phase 3·NCT06380751·788 enrolled

A Phase IIa, Open-label Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of Camizestrant in Combination With Atirmociclib in Participants With ER-positive, HER2-negative Advanced Breast Cancer (SERENA-1b)

Recruiting·AstraZeneca·Phase 2·NCT07427394·24 enrolled

Early Breast Cancer2 trials

CAMBRIA-1: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy With Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients With ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence

Recruiting·AstraZeneca·Phase 3·NCT05774951·4,300 enrolled

CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease

Active, not recruiting·AstraZeneca·Phase 3·NCT05952557·5,511 enrolled

Hepatic Impairment1 trial

Study to Investigate Hepatic Impairment on PK, Safety, Tolerability of Camizestrant in Post-Menopausal Female Subjects

Completed·AstraZeneca·Phase 1·NCT05790304·22 enrolled

Tics1 trial

A Study to Assess the Pharmacokinetics of Camizestrant (AZD9833) When Administered Alone and in Combination With Itraconazole

Completed·AstraZeneca·Phase 1·NCT05551897·14 enrolled

Breast Cancer1 trial

Efficacy and Safety of Camizestrant Plus Ribociclib in Patients With Breast Cancer

Not yet recruiting·MMedSIR·Phase 2·NCT07195227·150 enrolled

5 more indications

Midazolam1 trial

A Study to Investigate the Pharmacokinetics of Midazolam After Repeated Doses of Camizestrant (AZD9833) and to Investigate the Pharmacokinetics of Camizestrant When Administered Alone and in Combination With Carbamazepine in Healthy Post-Menopausal Female Participants

Completed·AstraZeneca·Phase 1·NCT06547164·40 enrolled

ER+ HER2- Advanced Breast Cancer1 trial

A Phase I/IIa, First-in-human, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors

Active, not recruiting·AstraZeneca·Preclinical·NCT06188520·55 enrolled

HER2-negative Breast Cancer1 trial

SERAFA-1: A Single Arm, Open Label, Multicentre, Phase IIIb Study Of Camizestrant Plus Ribociclib in 1st Line Treatment of ER Positive, HER2-negative Advanced Breast Cancer Patients

Recruiting·AstraZeneca·Phase 3·NCT07647328·150 enrolled

Estrogen1 trial

Phase II Window-of-Opportunity Study Evaluating the Pharmacodynamic Effects of Camizestrant in Early-Stage Estrogen Receptor-Positive Endometrial Cancer

Not yet recruiting·UUniversity Health Network, Toronto·Phase 2·NCT07840443·30 enrolled

Ovarian Cancer1 trial

A Modular Phase I/IIa, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

Active, not recruiting·Daiichi Sankyo·Preclinical·NCT04644068·702 enrolled

Regulatory

FDA Approval Timeline[4]

Details

Drug Info

Patent Landscape[5]

Related News